Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

A new study published in The Annals of Thoracic Surgery suggests that Medicaid expansion under the Affordable Care Act has ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in ...

Four leading companies CTMC, Iovance Therapeutics, KSQ, and TILT Biotherapeutics prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities.

Scientists at the Cancer Research Manchester Institute have created a new model of Lung Squamous Cell Carcinoma (LUSC), a common type of lung cancer, to study the development, activity, and ...

Lung cancer is the number one cancer killer in the world. Biomarker testing improves outcomes in stage IV non-small cell lung cancer (NSCLC), however its ...

"Most patients treated for small cell lung cancer experience rapid progression of disease and there is a high unmet need in the advanced setting," he added. "These interim results from the first ...

Moffitt is currently leading a clinical trial to test this approach in patients with non-small cell lung cancer. Researchers hope CD40L-enhanced TILs will become a next-generation standard in TIL ...